Business Wire

PATIENT-SAFETY-MOVEMENT

9.5.2018 16:32:11 CEST | Business Wire | Press release

Share
The Australian and New Zealand College of Anaesthetists Joins the Patient Safety Movement Foundation as a Committed Partner to Eliminate Preventable Harm in Hospitals

The Australian and New Zealand College of Anaesthetists (ANZCA) is partnering with the Patient Safety Movement Foundation (PSMF) in support of the mission to eliminate medical errors within hospitals - the 14 th leading cause of death worldwide. The announcement was made publicly at ANZCA’s Annual Scientific Meeting (ASM) in Sydney on May 8, 2018. Dr. Michael A. E. Ramsay, Anaesthetist, and Patient Safety Movement Foundation Board Member was present to sign the Commitment to Action Letter publicly alongside ANZCA President, Professor David A. Scott.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180509005874/en/

“We are thrilled to have the Australian and New Zealand College of Anaesthetists join us in our fight to eliminate preventable harm from hospitals. Through this partnership, we will reach the next generation of anaesthetists and recruit two important countries in our global effort to improve patient safety through the implementation of evidence-based processes,” explains Joe Kiani, Founder and Chairman of the Patient Safety Movement Foundation.

ANZCA runs one of Australasia’s largest specialist medical colleges and is the professional organisation representing nearly 6400 specialist anaesthetists and 1500 anaesthetists in training. ANZCA’s commitment represents the first by a major partner in Australia or New Zealand and joins 4,598 other committed hospitals and partners in 44 countries working towards the goal of eliminating preventable harm in hospitals.

“Patient harm and patient deaths occur in our hospitals daily, despite our best intentions. Many of these events are preventable if we apply existing knowledge, especially with the aid of new technologies. ANZCA welcomes this partnership which recognises our joint commitment to safety and quality in our specialty and improving patient safety,” said Professor Scott. “Initiatives such as this are so important for patients, hospitals and the specialty of anaesthesia.”

As a Committed Partner, ANZCA will work with the PSMF to improve patient outcomes with an acute focus on anesthesiology and perioperative care. Actions include:

    a.   Spreading the PSMF mission to ANZCA members;
 
b. Identifying Actionable Patient Safety Solutions (APSS) that align with ANZCA’s standards and/or policies and inviting members working in hospitals to implement APSS or similar processes with the aim of eliminating preventable patient deaths in hospitals;
 
c. Annually disseminating relevant APSS to ANZCA members;
 
d. Engaging with the PSMF at its annual meetings to develop and improve relevant APSS.
 

To learn more about the Patient Safety Movement Foundation, please visit www.patientsafetymovement.org .

About Patient Safety Movement Foundation: More than 200,000 people die every year in U.S. hospitals and 4.8 million worldwide in ways that could have been prevented. The Patient Safety Movement Foundation is a global non-profit which creates free tools for patients and hospitals. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to ZERO by 2020 (0X2020™). Improving patient safety will require a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The Patient Safety Movement Foundation works with all stakeholders to address the problems with actionable solutions for patient safety. The Foundation also convenes the World Patient Safety, Science & Technology Summit. The Summit brings together some of the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward ZERO preventable deaths by 2020. Visit patientsafetymovement.org.

About ANZCA: The Australian and New Zealand College of Anaesthetists (ANZCA) is the professional organisation for about 6400 specialist anaesthetists (Fellows) and 1500 anaesthetists in training (trainees). One of Australia's largest specialist medical colleges, ANZCA, along with its Faculty of Pain Medicine, is responsible for the training, examination and specialist accreditation of anaesthetists and pain medicine specialists and the standards of clinical practice in Australia and New Zealand. The College also plays a significant role in the advancement of anaesthesia in southeast Asia and South Pacific island countries.

Contact:

Patient Safety Movement Foundation
Tanya Lyon, Public Relations Manager
(949) 351-2858
tanya.lyon@patientsafetymovement.org
or
Australian & New Zealand College of Anaesthetists
Carolyn Jones, Media Manager
+61 3 8517 5303
cjones@anzca.edu.au

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release

Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release

A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release

New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release

Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release

Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye